Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Ophthalmology · Behçet's disease

Can Behçet's Disease Cause Blindness? Vision Risks

At a Glance

While severe, untreated eye inflammation from Behçet's disease can lead to blindness, modern treatments have drastically reduced this risk. Early diagnosis and medications called anti-TNF biologics are highly successful at quickly stopping inflammation, preventing flare-ups, and preserving vision.

In this answer

3 sections

01

How Behçet’s Affects the Eyes

02

Modern Treatments Protect Your Vision

03

Protecting Your Vision Over Time

It is completely understandable to be worried about losing your vision if you have eye inflammation from Behçet’s disease. The direct answer is that while severe, untreated eye inflammation from Behçet’s disease can lead to blindness, modern treatments have dramatically reduced this risk [1][2]. Decades ago, vision loss was a much more common outcome. Today, thanks to earlier diagnoses and powerful medications called biologics, doctors are highly successful at stopping the inflammation and preserving vision [3][4].

How Behçet’s Affects the Eyes

Behçet’s disease can cause inflammation inside the eye, a condition known as uveitis. When inflammation affects the back part of the eye (posterior uveitis) or the entire eye (panuveitis), it poses a greater risk to your vision [5][6]. Another serious complication is retinal vasculitis, which is inflammation of the blood vessels in the light-sensitive tissue at the back of the eye [7].

If left untreated or if it is not managed adequately, repeated attacks of inflammation can cause permanent damage to the delicate structures of the eye, which can eventually lead to permanent vision loss or blindness [8][2].

If you notice any sudden changes in your vision, such as blurriness, new floaters, eye pain, or photophobia (extreme sensitivity to light), you should contact your eye doctor immediately, as these are clear warning signs of an impending flare-up.

Modern Treatments Protect Your Vision

The outlook for eye involvement in Behçet’s disease has improved significantly over the last three decades [3]. The introduction of anti-TNF biologics—such as infliximab (typically given as an IV infusion at a clinic) and adalimumab (typically given as a self-injection at home)—has been a major breakthrough [9][10]. These medications specifically target and block the proteins in your immune system that cause inflammation.

Research shows that anti-TNF treatments are highly effective at:

  • Controlling inflammation quickly: They can quiet down a severe flare-up faster than many traditional medications [11][12].
  • Preventing future attacks: They significantly reduce the rate of recurrent eye inflammation, which is key to preventing long-term damage [13][14].
  • Protecting your vision: Early use of biologics helps stabilize your eyesight and improves your long-term visual outlook [15][16].
  • Reducing steroid use: Biologics can help you avoid the long-term side effects of high-dose corticosteroids [17][18].

Because biologics suppress the immune system, they do carry a risk of making you more vulnerable to infections [19][20]. For people with sight-threatening eye inflammation, doctors balance these risks against the benefits, and now frequently recommend anti-TNF biologics as a first-line treatment. They may be used alone or combined with traditional immunosuppressant medications, such as azathioprine or cyclosporine [21][22][23].

Protecting Your Vision Over Time

The most crucial step you can take is to work closely with an eye specialist (an ophthalmologist) who has experience treating uveitis [24]. Early diagnosis and prompt, aggressive treatment are essential to prevent permanent damage [2][5].

It is also important to maintain regular, routine eye exams even when your eyes feel fine and your disease is in remission. Low-grade inflammation can sometimes be asymptomatic, meaning you won’t feel or notice it, but it can still cause gradual structural damage to your eye over time.

Common questions in this guide

Can Behçet's disease lead to permanent vision loss?
Yes, repeated attacks of severe, untreated eye inflammation can cause permanent damage to the structures of the eye and lead to vision loss. However, with early diagnosis and modern treatments, this outcome is now much less common.
What are the warning signs of a Behçet's eye flare-up?
Warning signs of an impending eye flare-up include sudden blurriness, new floaters, eye pain, and extreme sensitivity to light (photophobia). If you experience any of these symptoms, you should contact your eye doctor immediately.
How do biologic medications help treat eye inflammation in Behçet's?
Anti-TNF biologics target and block the specific immune system proteins that cause inflammation. They work quickly to stop severe flare-ups, prevent future attacks, and protect your long-term vision without the long-term side effects of high-dose steroids.
Why do I need routine eye exams if my Behçet's disease is in remission?
Low-grade eye inflammation can sometimes happen without causing any noticeable symptoms. Regular eye exams can detect this hidden inflammation before it causes gradual structural damage to your eyes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific parts of my eyes are currently affected by inflammation (e.g., anterior, posterior, or panuveitis)?
  2. 2.Am I currently at risk for permanent vision loss based on my latest eye exam?
  3. 3.Would starting an anti-TNF biologic medication be appropriate for my specific type of eye inflammation, and how would it be administered?
  4. 4.What are the potential side effects or infection risks of the medications I am taking to manage my eye inflammation?
  5. 5.How often do I need to have comprehensive eye exams and imaging tests when I am not having a flare-up?
  6. 6.Who should I contact and what is the emergency protocol if I have sudden floaters, blurriness, or severe eye pain on a weekend or holiday?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can You Have a Healthy Pregnancy with Behçet's Disease?Does Behçet's Disease Cause Severe Fatigue & Tiredness?Will Behçet's Disease Burn Out With Age?Neuro-Behçet's vs MS: How Doctors Tell Them ApartHow Often Do You Need Eye Exams with Behçet's Disease?How to Manage Anxiety With Behçet's Disease?How to Relieve Behçet's Mouth Ulcer PainIs Behçet's Disease Contagious? What You Need to KnowIs Behçet's Disease Hereditary? HLA-B51 Gene ExplainedIs Behçet's Disease More Severe in Young Men?What Doctors Treat Behçet's Disease?What Do ESR & CRP Tests Mean in Behçet's Disease?What Is the Best Diet for Behçet's Disease?What is the Difference Between Behçet's and Crohn's?What Is the Difference Between Behçet's and Herpes?What is the Life Expectancy with Behçet's Disease?What Is the Pathergy Test for Behçet's Disease?What Triggers a Behçet's Disease Flare-Up? Key CausesWhy Avoid Blood Thinners for Behçet's Clots?

References

References (24)
  1. 1

    Rare presentation of Behçet's disease in a 22-year-old male with combined retinal artery and vein occlusions.

    Isaac B, Rehmani A, Angioletti L

    American journal of ophthalmology case reports 2025; (40()):102434 doi:10.1016/j.ajoc.2025.102434.

    PMID: 41049504
  2. 2

    Clinical Features of Behçet's Disease Uveitis.

    Yalçindag N, Oklar M

    Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society 2025; (39(4)):290-298 doi:10.4103/sjopt.sjopt_163_24.

    PMID: 41367832
  3. 3

    The Influence of Time on the Epidemiology and Clinical Manifestations of Behçet's Disease in Brazil.

    Hirata LT, Teixeira CEG, Magalhaes EP, et al.

    Journal of clinical medicine 2023; (12(22)) doi:10.3390/jcm12227008.

    PMID: 38002622
  4. 4

    Recent Clinical Features of Intraocular Inflammation in Hokkaido, Japan - Comparison with the Previous Decade.

    Iwata D, Namba K, Yamamoto T, et al.

    Ocular immunology and inflammation 2022; (30(4)):848-854 doi:10.1080/09273948.2020.1836565.

    PMID: 33571416
  5. 5

    [Uveitic glaucoma in Behçet's disease: When everything gets complicated].

    Belkhadir K, Boutimzine N, Tachfouti S, et al.

    Journal francais d'ophtalmologie 2020; (43(7)):635-641 doi:10.1016/j.jfo.2019.12.005.

    PMID: 32622636
  6. 6

    Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience.

    Sota J, Cantarini L, Vitale A, et al.

    Mediators of inflammation 2020; (2020()):6872402 doi:10.1155/2020/6872402.

    PMID: 32508524
  7. 7

    Ocular Manifestations, Conventional Fundus Fluorescein Angiographic Findings, and Relationship Between Angiographic Findings and Visual Acuity in Behçet's Disease.

    Bazvand F, Zarei M, Ebrahimiadib N, et al.

    Seminars in ophthalmology 2017; (32(6)):764-771 doi:10.1080/08820538.2016.1178310.

    PMID: 27715380
  8. 8

    Behçet's disease: How to diagnose and treat vascular involvement.

    Seyahi E

    Best practice & research. Clinical rheumatology 2016; (30(2)):279-295 doi:10.1016/j.berh.2016.08.002.

    PMID: 27886800
  9. 9

    Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report.

    Halilbasic M, Vodencarevic AN, Cosickic A, et al.

    Materia socio-medica 2021; (33(1)):78-81 doi:10.5455/msm.2021.33.78-81.

    PMID: 34012357
  10. 10

    Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

    Fabiani C, Vitale A, Emmi G, et al.

    Clinical rheumatology 2017; (36(1)):183-189 doi:10.1007/s10067-016-3480-x.

    PMID: 27853889
  11. 11

    Shaping the Future of Behçet's Uveitis Management: A Comprehensive Review of Efficacy, Challenges, and Prospects of Biologic Therapies.

    Li B, Li H, Huang Q, Zheng Y

    Ophthalmology and therapy 2023; (12(5)):2295-2321 doi:10.1007/s40123-023-00767-0.

    PMID: 37477857
  12. 12

    Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.

    Yang S, Huang Z, Liu X, et al.

    International immunopharmacology 2021; (93()):107430 doi:10.1016/j.intimp.2021.107430.

    PMID: 33581500
  13. 13

    Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet's Syndrome.

    Sota J, Gentileschi S, Perfetti MO, et al.

    Ophthalmology and therapy 2021; (10(4)):1129-1135 doi:10.1007/s40123-021-00387-6.

    PMID: 34458968
  14. 14

    Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.

    Fabiani C, Sota J, Vitale A, et al.

    Ocular immunology and inflammation 2019; (27(1)):34-39 doi:10.1080/09273948.2017.1391297.

    PMID: 29099660
  15. 15

    [Behçet's disease : Description and analysis of a French single-center retrospective study of 51 patients].

    Francois J, Moulinet T, Neiter E, et al.

    Journal francais d'ophtalmologie 2021; (44(5)):711-717 doi:10.1016/j.jfo.2020.04.064.

    PMID: 33741217
  16. 16

    Disease and Treatment-Specific Complications of Behçet Syndrome.

    Esatoglu SN, Ozguler Y, Hatemi G

    Current rheumatology reports 2024; (26(1)):1-11 doi:10.1007/s11926-023-01124-7.

    PMID: 37995045
  17. 17

    Efficacy of Biosimilar Adalimumab in the Treatment of Behçet's Uveitis.

    Soheilian M, Ebrahimiadib N, Hedayatfar A, et al.

    Ocular immunology and inflammation 2022; (30(6)):1495-1500 doi:10.1080/09273948.2021.1900276.

    PMID: 33826486
  18. 18

    Early administration of adalimumab for paediatric uveitis due to Behçet's disease.

    Hiyama T, Harada Y, Doi T, Kiuchi Y

    Pediatric rheumatology online journal 2019; (17(1)):29 doi:10.1186/s12969-019-0333-6.

    PMID: 31182107
  19. 19

    Indications, response, and side effects of biologic treatment in Behçet's disease: an 8-year study with follow-up.

    Shenavandeh S, Aflaki E, Jahromi MR, et al.

    Reumatologia 2024; (62(2)):101-108 doi:10.5114/reum/183467.

    PMID: 38799775
  20. 20

    Behçet's Disease with Bilateral Renal Infarction Due to Mucormycosis.

    Shimoyama K, Niwa T, Furukawa S, et al.

    Internal medicine (Tokyo, Japan) 2022; (61(7)):1077-1083 doi:10.2169/internalmedicine.7462-21.

    PMID: 34544946
  21. 21

    Biotherapies in Uveitis.

    Leclercq M, Desbois AC, Domont F, et al.

    Journal of clinical medicine 2020; (9(11)) doi:10.3390/jcm9113599.

    PMID: 33171664
  22. 22

    [Use of biotherapy in the management of Behçet's disease in a department of internal medicine].

    Wanvoegbe FA, Turcu A, Bach B, et al.

    La Revue de medecine interne 2019; (40(9)):570-573 doi:10.1016/j.revmed.2019.03.326.

    PMID: 30955904
  23. 23

    Risk factors, clinical features and treatment of Behçet's disease uveitis.

    Zhong Z, Su G, Yang P

    Progress in retinal and eye research 2023; (97()):101216 doi:10.1016/j.preteyeres.2023.101216.

    PMID: 37734442
  24. 24

    Pattern of Uveitis Associated with Behçet's Disease in an Egyptian Cohort.

    Abd El Latif E, Abdel Kader Fouly Galal M, Tawfik MA, et al.

    Clinical ophthalmology (Auckland, N.Z.) 2020; (14()):4005-4014 doi:10.2147/OPTH.S287298.

    PMID: 33262566

This page is for informational purposes only and does not replace professional medical advice. Always consult your ophthalmologist or rheumatologist about your specific vision symptoms and treatment plan.

Get notified when new evidence is published on Behçet disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.